Brief: TOT BIOPHARM International Posts H1 Revenue RMB520.603 Million
13/08/2024 15:04
Aug 13 (Reuters) - TOT BIOPHARM International H1 revenue RMB 520.603 million. * H1 cash flow from operating activities RMB 27.801 million * H1 net income RMB -31.559 million
Recent news on BioDlink International
See all newsCorrected: China's BioDlink International HY revenue falls (September 29)
Brief: Biodlink International To Deliver Ten Batches Of Monoclonal Antibody Intermediates To Wuxi Biologics
Brief: Biodlink International Says Shan Fu Resigns As Executive Director And Chairperson
Brief: BioDlink International Says WuXi XDC Cayman To Make Conditional Cash Offer For All Co Shares
Brief: HKEX Says Trading In Shares Of Biodlink International Will Be Halted At Dec 29